<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7261908\results\search\disease\results.xml">
  <result pre="Sciences, Fudan UniversityShanghaiChina[], 2Lindsley F. Kimball Research Institute, New York" exact="Blood" post="CenterNew York, NYUnited States Edited by: Nejat Duzgunes, University"/>
  <result pre="is permitted which does not comply with these terms. Abstract" exact="Infectious" post="diseases caused by human immunodeficiency virus (HIV) and other"/>
  <result pre="comply with these terms. Abstract Infectious diseases caused by human" exact="immunodeficiency" post="virus (HIV) and other highly pathogenic enveloped viruses, have"/>
  <result pre="health. Most antiviral drugs act as passive defenders to inhibit" exact="viral" post="replication inside the cell, while a few of them"/>
  <result pre="HIV, influenza virus, Zika virus (ZIKV), dengue virus (DENV), and" exact="herpes" post="simplex virus (HSV), and the potential use of PPVIs"/>
  <result pre="and the potential use of PPVIs for urgent treatment of" exact="infection" post="by newly emerging or re-emerging viruses. enveloped virus envelope"/>
  <result pre="emerging viruses fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Human" exact="immunodeficiency" post="virus (HIV), influenza virus and many other viruses are"/>
  <result pre="other viruses are enveloped viruses (Harrison, 2008). In most cases," exact="viral" post="envelope derives from the host cell membrane, while in"/>
  <result pre="envelope glycoproteins (Envs) are expressed on the surface of the" exact="viral" post="envelope and can play important roles in viral entry"/>
  <result pre="of the viral envelope and can play important roles in" exact="viral" post="entry into the target cell, including attaching the virus"/>
  <result pre="the host cell and mediating virus-cell membrane fusion, allowing the" exact="viral" post="genome to enter the host cell for replication (Vigant"/>
  <result pre="et al., 2015; Lu et al., 2016). The outbreak of" exact="infectious diseases" post="caused by highly pathogenic enveloped viruses, such as HIV,"/>
  <result pre="to develop safe and effective antiviral drugs to combat these" exact="infectious diseases" post="(Wang et al., 2017). Since the first antiviral drug"/>
  <result pre="al., 2017). Since the first antiviral drug for treatment of" exact="HIV infection," post="zidovudine, was approved for clinical use in 1987, the"/>
  <result pre="so far. They are mainly applied to treat and prevent" exact="infection" post="of HIV, herpes simplex virus (HSV), influenza virus, hepatitis"/>
  <result pre="are mainly applied to treat and prevent infection of HIV," exact="herpes" post="simplex virus (HSV), influenza virus, hepatitis B virus (HBV),"/>
  <result pre="prevent infection of HIV, herpes simplex virus (HSV), influenza virus," exact="hepatitis" post="B virus (HBV), and hepatitis C virus (HCV) (Chaudhuri"/>
  <result pre="simplex virus (HSV), influenza virus, hepatitis B virus (HBV), and" exact="hepatitis C" post="virus (HCV) (Chaudhuri et al., 2018). However, most of"/>
  <result pre="because they have to enter the virus-infected cells to inhibit" exact="viral" post="replication in the cells (Figure 1A). Therefore, these drugs"/>
  <result pre="outside the infected cells does not participate in inhibition of" exact="viral infection." post="FIGURE 1 Comparison of current antiviral drugs and the"/>
  <result pre="fusion inhibitors target the fusion process, while other inhibitors target" exact="viral" post="replication in HIV-infected cells, including nucleoside transcriptase inhibitors (NRTIs)"/>
  <result pre="they meet in the blood, by blocking the RBS on" exact="viral" post="Envs, changing the Env conformation or destructing the viral"/>
  <result pre="on viral Envs, changing the Env conformation or destructing the" exact="viral" post="structure. In contrast to â€œpassive defenders,â€� some antiviral agents"/>
  <result pre="â€œgate keepersâ€� to combat viruses outside cells. As mentioned above," exact="viral" post="entry can be divided into two steps: viral attachment"/>
  <result pre="mentioned above, viral entry can be divided into two steps:" exact="viral" post="attachment to cell receptor(s) and then viral fusion with"/>
  <result pre="into two steps: viral attachment to cell receptor(s) and then" exact="viral" post="fusion with the target cell. Therefore, â€œgate keepersâ€� can"/>
  <result pre="of virions to the target cell by blocking binding of" exact="viral" post="Env (e.g., gp120) to cellular the receptor (e.g., soluble"/>
  <result pre="et al., 2005), and fusion inhibitors that inhibit fusion between" exact="viral" post="and target cell membranes (e.g., enfuvirtide) (Jiang et al.,"/>
  <result pre="to their ability to block the receptor-binding site (RBS) on" exact="viral" post="Envs (Lu et al., 2012; Qi et al., 2017)."/>
  <result pre="inactivators vary: they can bind and block the RBS on" exact="viral" post="Envs (Chen et al., 2014), or induce the conformational"/>
  <result pre="other inactivators may bind to the Env stem or the" exact="viral" post="lipid membrane, to disrupt the integrity of the viral"/>
  <result pre="the viral lipid membrane, to disrupt the integrity of the" exact="viral" post="envelope or lead to the release of viral genetic"/>
  <result pre="of the viral envelope or lead to the release of" exact="viral" post="genetic materials (Yu et al., 2017) (Figure 1B). Because"/>
  <result pre="development as novel antiviral drugs for the urgent treatment of" exact="infection" post="by the highly pathogenic emerging and re-emerging viruses. In"/>
  <result pre="antiviral drugs and the potential application for urgent treatment of" exact="infection" post="by newly emerging and re-emerging viruses. Protein- and Peptide-Based"/>
  <result pre="emerging and re-emerging viruses. Protein- and Peptide-Based HIV Inactivators Human" exact="immunodeficiency" post="virus primarily targets the immune system, including CD4+ T"/>
  <result pre="of the HIV-infected patient is gradually destroyed, eventually resulting in" exact="acquired immunodeficiency syndrome" post="(AIDS) and death (Moir et al., 2011). More than"/>
  <result pre="the HIV-infected patient is gradually destroyed, eventually resulting in acquired" exact="immunodeficiency" post="syndrome (AIDS) and death (Moir et al., 2011). More"/>
  <result pre="HIV-infected patient is gradually destroyed, eventually resulting in acquired immunodeficiency" exact="syndrome" post="(AIDS) and death (Moir et al., 2011). More than"/>
  <result pre="et al., 2015). They must enter HIV-infected cells to inhibit" exact="viral" post="replication. The only peptide-based HIV fusion inhibitor, enfuvirtide (also"/>
  <result pre="thus also having the problem of low utilization rate. Human" exact="immunodeficiency" post="virus type 1 (HIV-1) envelope glycoprotein is originally expressed"/>
  <result pre="having the problem of low utilization rate. Human immunodeficiency virus" exact="type 1" post="(HIV-1) envelope glycoprotein is originally expressed as the gp160"/>
  <result pre="amino acids in length (Figure 2A), which is cleaved by" exact="viral" post="protease to form a highly glycosylated trimer of heterodimers,"/>
  <result pre="(FP), N-terminal heptad repeat (NHR), C-terminal heptad repeat (CHR), membrane-proximal" exact="external" post="region (MPER), transmembrane region (TM), and cytoplasmic region (CP)."/>
  <result pre="into the target cell membrane to form a prehairpin fusion" exact="intermediate" post="conformation (PFI) (Melikyan, 2008). Then, NHRs and CHRs of"/>
  <result pre="to form a six-helix bundle (6-HB) core structure, bringing the" exact="viral" post="envelope and cell membrane into close proximity to achieve"/>
  <result pre="the HIV-1 Env to the cellular receptor(s) and fusion of" exact="viral" post="envelope with the target cell membrane. Binding of gp120"/>
  <result pre="into the target cell membrane and formation of the pre-fusion" exact="intermediate" post="(PFI) state. The N- and C-terminal heptad repeats (NHRs"/>
  <result pre="to form a six-helix bundle (6-HB) structure, which brings the" exact="viral" post="envelope and target cell membrane together to achieve fusion."/>
  <result pre="HIV-1 inactivator, 2DLT, for inactivating cell-free HIV-1 virions in the" exact="absence of" post="target cells (Sanders, 2013). 2DLT, a bivalent recombinant protein,"/>
  <result pre="in HIV-1 gp120 triggers the formation of a gp120/gp41 pre-fusion" exact="intermediate" post="(PFI), in which gp41 NHR is partially exposed (Haim"/>
  <result pre="could effectively inactivate cell-free HIV-1 virions, including laboratory-adapted strains and" exact="primary" post="isolates of different subtypes with an EC50 (Half maximal"/>
  <result pre="with these drugs brought about synergism or strong synergism against" exact="infection" post="of both X4 and R5 HIV-1 strains (Xu et"/>
  <result pre="gp120 on HIV-1 and inactivate the cell-free virions in the" exact="absence of" post="host cells because virions would lose their ability to"/>
  <result pre="Indeed, in vitro studies indicated that sCD4 could inhibit HIV-1" exact="infection" post="with IC50 (half maximal inhibitory concentration) values between 40"/>
  <result pre="Iâ€&quot;II clinical trials showed that intravenously administered sCD4 effectively reduced" exact="viral" post="titers in sera without causing obvious toxicity. However, the"/>
  <result pre="toxicity. However, the half-life of sCD4 is short, leading to" exact="viral" post="relapse within a short time after treatment (Kahn et"/>
  <result pre="of sCD4 is short, leading to viral relapse within a" exact="short" post="time after treatment (Kahn et al., 1990; Schooley et"/>
  <result pre="could not effectively inhibit HIV-1 infection, but rather enhanced the" exact="infection" post="of some HIV-1 clinical isolates in host cells, including"/>
  <result pre="coreceptor on the host cell and, hence, fusion between the" exact="viral" post="envelope and host cell membrane (Sullivan et al., 1998)."/>
  <result pre="fusion and infection. Unlike sCD4, CD4-IgG2 could not enhance HIV-1" exact="infection" post="in CD4- CCR5+ cells. Like the broadly neutralizing antibodies"/>
  <result pre="CD4-IgG2 could effectively neutralize a panel of laboratory-adapted strains and" exact="primary" post="isolates of HIV-1 with different subtypes with IC50s from"/>
  <result pre="(Trkola et al., 1995), and it was capable of reducing" exact="viral" post="titers in rodent models (Gauduin et al., 1998). The"/>
  <result pre="an 80% response rate and âˆ¼0.5 log10 mean reductions in" exact="viral" post="load for 4â€&quot;6 weeks after treatment were mediated by"/>
  <result pre="et al., 2004). However, the concern about the enhancement of" exact="infection" post="of some HIV-1 strains caused by sCD4- or CD4-containing"/>
  <result pre="in CD4 and scyllatoxinâ€™s the Î²-hairpin region of scyllatoxin, a" exact="short" post="scorpion toxin, the side chains of nine residues in"/>
  <result pre="gp120 with an IC50 of 40 Î¼M and suppressed the" exact="infection" post="of HIV-1 X4 and R5 strains with IC50s ranging"/>
  <result pre="found that both mD1.1 and mD1.2 could effectively neutralize HIV-1" exact="primary" post="isolates (Sharma et al., 2005). Subsequently, they identified an"/>
  <result pre="more potent than D1D2 and mD1.2 in inhibiting R5-tropic HIV-1" exact="primary" post="isolates, Bal and JRFL (Chen et al., 2014). To"/>
  <result pre="bispecific multivalent fusion proteins, 2Dm2m and 4Dm2m, which could inhibit" exact="infection" post="by all HIV-1 strains tested, including 41 HIV-1 isolates"/>
  <result pre="developed into new anti-HIV drugs for treatment and prevention of" exact="HIV infection." post="By screening phage display libraries of random 12-mer peptides,"/>
  <result pre="and the coreceptor CCR5, both of which are crucial for" exact="viral" post="entry. Therefore, 12p1 may act as an HIV-1 attachment"/>
  <result pre="affinity than that of 12p1, causing gp120 shedding from the" exact="viral" post="particles, and thereby irreversibly inactivating the virions (Aneja et"/>
  <result pre="segmented negative-sense, single-stranded RNA genomes (Palese and Shaw, 2007). Influenza" exact="virus infection" post="can lead to a high fever, cough, headache, sore"/>
  <result pre="negative-sense, single-stranded RNA genomes (Palese and Shaw, 2007). Influenza virus" exact="infection" post="can lead to a high fever, cough, headache, sore"/>
  <result pre="and D, on the basis of antigenic properties of the" exact="viral" post="nucleoprotein (NP) and matrix protein (M). Since most annual"/>
  <result pre="as amantadine (Bright et al., 2006) and rimantadine, which block" exact="viral" post="uncoating, and (2) neuraminidase inhibitors (NAIs), including oseltamivir (de"/>
  <result pre="et al., 2005), zanamivir, peramivir, and laninamivir octanoate, which inhibit" exact="viral" post="release. However, the continual emergence of drug resistance seriously"/>
  <result pre="antiviral drug, baloxavir marboxil (trade name Xofluza), which can inhibit" exact="viral" post="replication in cells, was approved by Japanese and United"/>
  <result pre="by Japanese and United States FDA and proved effective against" exact="infection" post="by influenza virus strains resistant to current anti-influenza drugs"/>
  <result pre="et al., 2020). Also, these drugs mentioned above must inhibit" exact="viral infection" post="in the presence of target cells, instead of inactivating"/>
  <result pre="al., 2020). Also, these drugs mentioned above must inhibit viral" exact="infection" post="in the presence of target cells, instead of inactivating"/>
  <result pre="with the C-terminal transmembrane domain (TMD) anchoring HA2 in the" exact="viral" post="envelope, to create a pre-hairpin conformation (Bullough et al.,"/>
  <result pre="of HA protein to the cellular receptor(s) and fusion of" exact="viral" post="envelope with endosomal membrane. To initiate the entry process,"/>
  <result pre="with the C-terminal transmembrane domain (TMD) anchoring HA2 in the" exact="viral" post="envelope, creating a pre-hairpin conformation (extended intermediate). Afterward, the"/>
  <result pre="which then further collapses into a six-helix bundle, bringing the" exact="viral" post="envelope and endosomal membrane together for fusion. The pre-fusion"/>
  <result pre="lines and arrow. Because HA plays a key role in" exact="viral" post="attachment and membrane fusion, it is the promising target"/>
  <result pre="that exert their virucidal activity by non-specific interaction with the" exact="viral" post="lipid membranes, urumin could specifically interact with the conserved"/>
  <result pre="action, proteins designed in this way are expected to possess" exact="viral" post="inactivation abilities; however, a viral inactivation experiment was not"/>
  <result pre="way are expected to possess viral inactivation abilities; however, a" exact="viral" post="inactivation experiment was not performed in this study. Therefore,"/>
  <result pre="bind the RBSs in H1 and H3 HAs and inhibit" exact="infection" post="by the A/Puerto Rico/8/34 (H1N1) and A/Aichi/2/68 (H3N2) strains"/>
  <result pre="indicated that one of these peptides, C18-LVRPLAL, could strongly inhibit" exact="infection" post="by the A/Aichi/2/68 (H3N2) strain with an IC50 value"/>
  <result pre="receptor antagonist, which binds to the cell receptor to inhibit" exact="viral infection." post="Also, it has been the key immunogen of currently"/>
  <result pre="genome, are enveloped viruses transmitted by hematophagous mosquito vectors. Flavivirus" exact="infection" post="may cause neurological, viscerotrophic or hemorrhagic diseases (Slon Campos"/>
  <result pre="comprised of a variety of human pathogens, including DENV, ZIKV," exact="yellow fever" post="virus (YFV), West Nile virus (WNV), and so on"/>
  <result pre="virus (WNV), and so on (Kuno et al., 1998). Zika" exact="virus infection" post="usually causes mild symptoms, such as rash, fever, headache,"/>
  <result pre="(WNV), and so on (Kuno et al., 1998). Zika virus" exact="infection" post="usually causes mild symptoms, such as rash, fever, headache,"/>
  <result pre="some cases, such as Guillain-BarrÃ© syndrome, meningo-encephalitis and myelitis. ZIKV" exact="infection" post="of pregnant women may cause microcephaly in their fetuses"/>
  <result pre="meningo-encephalitis and myelitis. ZIKV infection of pregnant women may cause" exact="microcephaly" post="in their fetuses and newborns (Cui et al., 2017;"/>
  <result pre="serotypes of DENV (DENV-1, 2, 3, and 4) constitute the" exact="primary" post="mosquito-borne viral pathogen. DENV is endemic in more than"/>
  <result pre="DENV (DENV-1, 2, 3, and 4) constitute the primary mosquito-borne" exact="viral" post="pathogen. DENV is endemic in more than 100 countries"/>
  <result pre="million people each year, of which 96 million people exhibit" exact="disease" post="symptoms (Bhatt et al., 2013). After DENV infection, some"/>
  <result pre="while others might suffer from more severe diseases, such as" exact="dengue hemorrhagic fever" post="and shock syndrome (DHF/DSS) (Halstead, 2007). Till now, only"/>
  <result pre="more severe diseases, such as dengue hemorrhagic fever and shock" exact="syndrome" post="(DHF/DSS) (Halstead, 2007). Till now, only several small molecule"/>
  <result pre="below the E protein ectodomain and partially embedded in the" exact="viral" post="envelope (Figure 4C) (Zhang et al., 2013). The M"/>
  <result pre="pH-sensitive chaperone, plays a vital role during the process of" exact="viral infection" post="and maturation (Li et al., 2008). As shown in"/>
  <result pre="chaperone, plays a vital role during the process of viral" exact="infection" post="and maturation (Li et al., 2008). As shown in"/>
  <result pre="(Li et al., 2008). As shown in Figure 4B, DENV" exact="infection" post="is initiated by binding of domain III of E"/>
  <result pre="domain III in each subunit is reversely folded, bringing the" exact="viral" post="envelope and the endosomal membrane into close proximity for"/>
  <result pre="DENV E protein to the cellular receptor(s) and fusion of" exact="viral" post="envelope with the endosome membrane. Binding of E protein"/>
  <result pre="III in each subunit is reversely folded to promote the" exact="viral" post="envelope and the endosomal membrane into close proximity for"/>
  <result pre="sites, including the lateral loop of domain III and the" exact="viral" post="lipid membrane. Notably, potential inactivators remaining to be tested"/>
  <result pre="region (residues 692â€&quot;724) with amphipathicity and membrane-binding ability, could inhibit" exact="infection" post="of all four serotypes of DENV with IC50 values"/>
  <result pre="It was also effective against some other flaviviruses, such as" exact="yellow fever" post="virus (YFV) (Lok et al., 2012). Further studies of"/>
  <result pre="that it can irreversibly inactivate virions by directly interacting with" exact="viral" post="lipid membranes and forming holes at the five-fold vertices"/>
  <result pre="membranes and forming holes at the five-fold vertices in the" exact="viral" post="envelope, allowing the release of viral genomic RNA (Schmidt"/>
  <result pre="five-fold vertices in the viral envelope, allowing the release of" exact="viral" post="genomic RNA (Schmidt et al., 2010a, b; Lok et"/>
  <result pre="protein (residues 421â€&quot;453), and similarly Z2 was shown to inhibit" exact="infection" post="by different strains of ZIKV and other flaviviruses, including"/>
  <result pre="EC50 value of âˆ¼2.5 Î¼M, by forming pores in the" exact="viral" post="envelope, allowing the release of the viral RNA genome"/>
  <result pre="pores in the viral envelope, allowing the release of the" exact="viral" post="RNA genome (Yu et al., 2017). Although Z2 could"/>
  <result pre="in the placenta or umbilical cord, thus effectively reducing the" exact="viral" post="titers in the fetal brain. In addition to the"/>
  <result pre="II beta sheet connection (residues 41â€&quot;60), respectively, could inhibit DENV-2" exact="infection" post="with IC50 values of 8 and 7 Î¼M, respectively."/>
  <result pre="treated with DN57opt or 1OAN1 became rough, suggesting that the" exact="viral" post="envelope may have been damaged (Costin et al., 2010)."/>
  <result pre="By molecular docking analysis, Panya et al. (2014) identified several" exact="short" post="peptides targeting the hydrophobic pocket. They found that the"/>
  <result pre="that the dipeptide Glu-Phe (EF for short) could inhibit the" exact="infection" post="of all four DENV serotypes, but it was the"/>
  <result pre="Alhoot et al. (2013) screened for anti-DENV peptides targeting a" exact="short" post="sequence (residues 380â€&quot;389) in the lateral loop of DENV-2"/>
  <result pre="They found that peptides DET2 and DET4 could inhibit DENV-2" exact="infection" post="with IC50 values of 500 and 35 Î¼M, respectively."/>
  <result pre="these peptides could inactivate virions by disrupting integrity of the" exact="viral" post="envelope. Other studies showed that M protein of DENV"/>
  <result pre="ectodomain of M protein, and found that it could inhibit" exact="infection" post="of four serotypes of DENV with IC50 values ranging"/>
  <result pre="in HIV gp120 (Huerta et al., 2008). In addition, the" exact="viral" post="inactivation activities of many peptides have not been verified"/>
  <result pre="viruses with double-stranded DNA genomes, can bring about lifelong, latent" exact="infections" post="(Pellet and Roizman, 2013). These viruses are classified as"/>
  <result pre="sequences and biological properties (Davison et al., 2009). In alpha-herpesviruses," exact="herpes" post="simplex virus types 1 and 2 (HSV-1 and HSV-2)"/>
  <result pre="properties (Davison et al., 2009). In alpha-herpesviruses, herpes simplex virus" exact="types 1 and 2" post="(HSV-1 and HSV-2) and varicella-zoster virus (VZV) are human"/>
  <result pre="oral and genital ulcers to devastating encephalitis. Following the initial" exact="infection" post="at a peripheral site, it will establish a lifetime"/>
  <result pre="ulcers to devastating encephalitis. Following the initial infection at a" exact="peripheral" post="site, it will establish a lifetime latency in sensory"/>
  <result pre="sensory neurons, which can be reactivated by some internal or" exact="external" post="stimuli, including fever, immunosuppression, trauma, etc. (Roizman et al.,"/>
  <result pre="antiviral agent and the reference for treating HSV infection. However," exact="viral" post="resistance to ACV has become a critical clinical problem,"/>
  <result pre="In addition, these drugs all exert antiviral effects by targeting" exact="viral" post="DNA polymerase in target cells, therefore no antiviral drugs"/>
  <result pre="of other enveloped viruses using a single Env to mediate" exact="viral" post="fusion process, HSV utilize a set of surface glycoproteins"/>
  <result pre="HSV-1 as the example, HSV-1 gD (369-amino acids) is a" exact="type I" post="membrane glycoprotein with a short cytoplasmic tail and an"/>
  <result pre="(369-amino acids) is a type I membrane glycoprotein with a" exact="short" post="cytoplasmic tail and an ectodomain with an immunoglobulin-like core"/>
  <result pre="shown in Figure 5A, HSV-1 gH is an 838-amino acid" exact="type I" post="membrane glycoprotein comprised of a single pass transmembrane domain,"/>
  <result pre="membrane glycoprotein comprised of a single pass transmembrane domain, a" exact="short" post="cytoplasmic tail and an ectodomain (Gompels and Minson, 1986)."/>
  <result pre="structure of gH/gL complex does not resemble any other known" exact="viral" post="fusogen structure. Therefore, the gB-gH/gL complex is key for"/>
  <result pre="may enter cells through endocytosis or direct fusion of the" exact="viral" post="envelope with cellular membrane, relying on the target cell"/>
  <result pre="(Nicola, 2016); notably, both routes require the same set of" exact="viral" post="glycoproteins (Nicola and Straus, 2004). HSV entry through direct"/>
  <result pre="cell receptors, (2) intracellular signaling, and (3) fusion of the" exact="viral" post="envelope with host cell membrane (Connolly et al., 2011)."/>
  <result pre="HSV-1 and HSV-2 have been confirmed: a member of the" exact="tumor" post="necrosis factor (TNF) receptor family, herpesvirus entry mediator (HVEM);"/>
  <result pre="also bind to specific cell receptors, such as paired immunoglobulin-like" exact="type 2" post="receptor (PILR)Î± (Satoh et al., 2008), myelin-associated glycoprotein (MAG)"/>
  <result pre="inactivate cell-free HSV virions has not been clarified. Meanwhile, the" exact="viral" post="inactivation activities of these peptide inactivators are relatively weak,"/>
  <result pre="the design of protein- and peptide-based HSV inactivators. Discussion The" exact="lower" post="eukaryotic organisms, such as invertebrates and plants, only possess"/>
  <result pre="including some antimicrobial peptides (AMPs) that can non-specifically destroy the" exact="viral" post="envelope and inactivate the cell-free virions (Ganz, 2003; Seo"/>
  <result pre="our definition of virus inactivators described before, many of the" exact="viral" post="neutralizing antibodies with the ability to irreversibly inactivate cell-free"/>
  <result pre="actively attack and inactivate cell-free virions have certain advantages against" exact="viral" post="infections (Burton, 2002). Nonetheless, how these neutralizing antibodies inactivate"/>
  <result pre="attack and inactivate cell-free virions have certain advantages against viral" exact="infections" post="(Burton, 2002). Nonetheless, how these neutralizing antibodies inactivate cell-free"/>
  <result pre="reason, they were not discussed in detail in this review." exact="Viral" post="fusion proteins in different oligomeric states and structures can"/>
  <result pre="in DENV and ZIKV E protein; and (4) for performing" exact="viral" post="inactivation assays, such as those for evaluating inactivation activities"/>
  <result pre="successfully applied to design a variety of virus inactivators targeting" exact="viral" post="Envs, and they can also be used for the"/>
  <result pre="inactivators against enveloped viruses, we can now design and develop" exact="viral" post="inactivators targeting key proteins involved in the entry process"/>
  <result pre="of a non-enveloped virion is initiated by binding of the" exact="viral" post="capsid protein to the cell receptor, followed by entry"/>
  <result pre="occur in the cell endosome, the receptor-binding domains in the" exact="viral" post="capsid protein seem to be the best targets for"/>
  <result pre="action mechanisms of PPVIs include (1) blocking the RBS on" exact="viral" post="Envs, (2) inducing conformational changes of viral Env, causing"/>
  <result pre="the RBS on viral Envs, (2) inducing conformational changes of" exact="viral" post="Env, causing the virion to lose the ability to"/>
  <result pre="cell, or (3) binding to the Env stem or the" exact="viral" post="lipid membrane, to disrupt the integrity of the viral"/>
  <result pre="the viral lipid membrane, to disrupt the integrity of the" exact="viral" post="envelope or lead to the release of viral genetic"/>
  <result pre="of the viral envelope or lead to the release of" exact="viral" post="genetic materials. Apart from these, exact mechanisms of some"/>
  <result pre="cost, PPVIs are generally more expensive for long-term treatment of" exact="chronic" post="viral infection. Lentiviral vector-based gene therapy to secret a"/>
  <result pre="PPVIs are generally more expensive for long-term treatment of chronic" exact="viral infection." post="Lentiviral vector-based gene therapy to secret a PPVI continuously"/>
  <result pre="to secret a PPVI continuously can be one choice to" exact="lower" post="the cost (Perez et al., 2005; Egerer et al.,"/>
  <result pre="encoding secreted anti-HIV proteins including sCD4, which could prohibit the" exact="infection" post="of both gene-modified and unmodified cells. They further investigated"/>
  <result pre="(HSPCs) into humanized mice. The results demonstrated a reduction of" exact="viral" post="load over time in humanized mice capable of secreting"/>
  <result pre="and re-emerging virus infections, e.g., Ebola virus or Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) infection. Drugs are especially key in"/>
  <result pre="re-emerging virus infections, e.g., Ebola virus or Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) infection. Drugs are especially key in the"/>
  <result pre="et al., 2019). In fact, characteristics of medication against these" exact="viral" post="infections are short-term use (1â€&quot;3 weeks), rapid application and"/>
  <result pre="al., 2019). In fact, characteristics of medication against these viral" exact="infections" post="are short-term use (1â€&quot;3 weeks), rapid application and high"/>
  <result pre="safe (Zaman et al., 2019), and in this circumstance, their" exact="short" post="half-lives become an advantage instead because they will not"/>
  <result pre="more PPVIs will be developed for treatment and prevention of" exact="viral" post="infections, particularly useful for combating the pandemics or epidemics"/>
  <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
  <result pre="by grants from the National Mega-Projects of China for Major" exact="Infectious" post="Diseases (2018ZX10301403 to LL) and the National Natural Science"/>
  <result pre="grants from the National Mega-Projects of China for Major Infectious" exact="Diseases" post="(2018ZX10301403 to LL) and the National Natural Science Foundation"/>
  <result pre="with high quality. References References AkkarawongsaR.PocaroN. E.CaseG.KolbA. W.BrandtC. R. (2009)." exact="Multiple" post="peptides homologous to herpes simplex virus type 1 glycoprotein"/>
  <result pre="References AkkarawongsaR.PocaroN. E.CaseG.KolbA. W.BrandtC. R. (2009). Multiple peptides homologous to" exact="herpes" post="simplex virus type 1 glycoprotein B inhibit viral infection.Antimicrob."/>
  <result pre="W.BrandtC. R. (2009). Multiple peptides homologous to herpes simplex virus" exact="type 1" post="glycoprotein B inhibit viral infection.Antimicrob. Agents Chemother.53987â€&quot;996. 10.1128/AAC.00793-0819104014 AlhootM."/>
  <result pre="homologous to herpes simplex virus type 1 glycoprotein B inhibit" exact="viral" post="infection.Antimicrob. Agents Chemother.53987â€&quot;996. 10.1128/AAC.00793-0819104014 AlhootM. A.RathinamA. K.WangS. M.ManikamR.SekaranS. D."/>
  <result pre="Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes" exact="primary" post="HIV type 1 isolates.AIDS Res. Hum. Retroviruses11533â€&quot;539. 10.1089/aid.1995.11.5337576908 AnejaR.RashadA."/>
  <result pre="characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV" exact="type 1" post="isolates.AIDS Res. Hum. Retroviruses11533â€&quot;539. 10.1089/aid.1995.11.5337576908 AnejaR.RashadA. A.LiH.Kalyana SundaramR. V.DuffyC.BaileyL."/>
  <result pre="(2010). Non-muscle myosin IIA is a functional entry receptor for" exact="herpes" post="simplex virus-1.Nature467859â€&quot;862. 10.1038/nature0942020944748 AriiJ.HirohataY.KatoA.KawaguchiY. (2015). Nonmuscle myosin heavy chain"/>
  <result pre="virus-1.Nature467859â€&quot;862. 10.1038/nature0942020944748 AriiJ.HirohataY.KatoA.KawaguchiY. (2015). Nonmuscle myosin heavy chain IIb mediates" exact="herpes" post="simplex virus 1 entry.J. Virol.891879â€&quot;1888. 10.1128/JVI.03079-1425428876 AriiJ.KawaguchiY. (2018). The"/>
  <result pre="J. (2010a). Cascade of events governing cell-cell fusion induced by" exact="herpes" post="simplex virus glycoproteins gD, gH/gL, and gB.J. Virol.8412292â€&quot;12299. 10.1128/JVI.01700-1020861251"/>
  <result pre="gB.J. Virol.8412292â€&quot;12299. 10.1128/JVI.01700-1020861251 AtanasiuD.SawW. T.EisenbergR. J.CohenG. H. (2016). Regulation of" exact="herpes" post="simplex virus glycoprotein-induced cascade of events governing cell-cell fusion.J."/>
  <result pre="(2007). Bimolecular complementation reveals that glycoproteins gB and gH/gL of" exact="herpes" post="simplex virus interact with each other during cell fusion.Proc."/>
  <result pre="chimeras composed of conserved domains of the pseudorabies virus and" exact="herpes" post="simplex virus 1 homologs.J. Virol.90421â€&quot;432. 10.1128/JVI.01985-1526491153 BoschB. J.BodewesR.de VriesR."/>
  <result pre="distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza" exact="virus infection" post="in ferrets.J. Virol.8410366â€&quot;10374. 10.1128/JVI.01035-1020686020 BrightR. A.ShayD. K.ShuB.CoxN. J.KlimovA. I."/>
  <result pre="types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus" exact="infection" post="in ferrets.J. Virol.8410366â€&quot;10374. 10.1128/JVI.01035-1020686020 BrightR. A.ShayD. K.ShuB.CoxN. J.KlimovA. I."/>
  <result pre="T.et al. (2019). Surface plasmon resonance reveals direct binding of" exact="herpes" post="simplex virus glycoproteins gH/gL to gD and locates a"/>
  <result pre="L.Torres-FloresJ. (2016). Peptides derived from glycoproteins H and B of" exact="herpes" post="simplex virus type 1 and herpes simplex virus type"/>
  <result pre="derived from glycoproteins H and B of herpes simplex virus" exact="type 1" post="and herpes simplex virus type 2 are capable of"/>
  <result pre="H and B of herpes simplex virus type 1 and" exact="herpes" post="simplex virus type 2 are capable of blocking herpetic"/>
  <result pre="of herpes simplex virus type 1 and herpes simplex virus" exact="type 2" post="are capable of blocking herpetic infection in vitro.Intervirology59235â€&quot;242. 10.1159/00046413428329739"/>
  <result pre="herpes simplex virus type 2 are capable of blocking herpetic" exact="infection" post="in vitro.Intervirology59235â€&quot;242. 10.1159/00046413428329739 ChaikenI.RashadA. A. (2015). Peptide triazole inactivators"/>
  <result pre="to the outer leaflet of the plasma membrane and promote" exact="viral" post="entry.PLoS Pathog.14:e100676610.1371/journal.ppat.1006766 CheshenkoN.TrepanierJ. B.StefanidouM.BuckleyN.GonzalezP.JacobsW.et al. (2013). HSV activates Akt"/>
  <result pre="(2013). HSV activates Akt to trigger calcium release and promote" exact="viral" post="entry: novel candidate target for treatment and suppression.FASEB J.272584â€&quot;2599."/>
  <result pre="10.1038/nsmb.183720601960 CocchiF.FuscoD.MenottiL.GianniT.EisenbergR. J.CohenG. H.et al. (2004). The soluble ectodomain of" exact="herpes" post="simplex virus gD contains a membrane-proximal pro-fusion domain and"/>
  <result pre="Rev. Microbiol.9369â€&quot;381. 10.1038/nrmicro254821478902 CostinJ. M.JenwitheesukE.LokS. M.HunspergerE.ConradsK. A.FontaineK. A.et al. (2010)." exact="Structural" post="optimization and de novo design of dengue virus entry"/>
  <result pre="al. (2017). Visual and motor deficits in grown-up mice with" exact="congenital" post="zika virus infection.EBioMedicine20193â€&quot;201. 10.1016/j.ebiom.2017.04.02928583742 CulshawA.MongkolsapayaJ.ScreatonG. (2018). The immunology of"/>
  <result pre="High concentrations of recombinant soluble CD4 are required to neutralize" exact="primary" post="human immunodeficiency virus type 1 isolates.Proc. Natl. Acad. Sci."/>
  <result pre="of recombinant soluble CD4 are required to neutralize primary human" exact="immunodeficiency" post="virus type 1 isolates.Proc. Natl. Acad. Sci. U.S.A.876574â€&quot;6578. 10.1073/pnas.87.17.65742395859"/>
  <result pre="soluble CD4 are required to neutralize primary human immunodeficiency virus" exact="type 1" post="isolates.Proc. Natl. Acad. Sci. U.S.A.876574â€&quot;6578. 10.1073/pnas.87.17.65742395859 DavisonA. J.EberleR.EhlersB.HaywardG. S.McGeochD."/>
  <result pre="Di GiovineP.SettembreE. C.BhargavaA. K.LuftigM. A.LouH.CohenG. H.et al. (2011). Structure of" exact="herpes" post="simplex virus glycoprotein D bound to the human receptor"/>
  <result pre="with many characters.Viruses4800â€&quot;832. 10.3390/v405080022754650 EkiertD. C.BhabhaG.ElsligerM. A.FriesenR. H.JongeneelenM.ThrosbyM.et al. (2009)." exact="Antibody" post="recognition of a highly conserved influenza virus epitope.Science324246â€&quot;251. 10.1126/science.117149119251591"/>
  <result pre="target cells.Gene Ther.21175â€&quot;187. 10.1038/gt.2013.7024305417 FalkenhagenA.SinghJ.AsadS.LeontyevD.ReadS.Zuniga-PfluckerJ. C.et al. (2017). Control of" exact="HIV infection" post="in vivo using gene therapy with a secreted entry"/>
  <result pre="cells.Gene Ther.21175â€&quot;187. 10.1038/gt.2013.7024305417 FalkenhagenA.SinghJ.AsadS.LeontyevD.ReadS.Zuniga-PfluckerJ. C.et al. (2017). Control of HIV" exact="infection" post="in vivo using gene therapy with a secreted entry"/>
  <result pre="HIV-1.Nat. Med.111170â€&quot;1172. 10.1038/nm131916205738 FerrerM.HarrisonS. C. (1999). Peptide ligands to human" exact="immunodeficiency" post="virus type 1 gp120 identified from phage display libraries.J."/>
  <result pre="10.1038/nm131916205738 FerrerM.HarrisonS. C. (1999). Peptide ligands to human immunodeficiency virus" exact="type 1" post="gp120 identified from phage display libraries.J. Virol.735795â€&quot;5802.10364331 FleishmanS. J.WhiteheadT."/>
  <result pre="of influenza hemagglutinin.Science332816â€&quot;821. 10.1126/science.120261721566186 GaldieroS.FalangaA.TaralloR.RussoL.GaldieroE.CantisaniM.et al. (2013). Peptide inhibitors against" exact="herpes" post="simplex virus infections.J. Pept. Sci.19148â€&quot;158. 10.1002/psc.248923389903 GallagherJ. R.SawW. T.AtanasiuD.LouH.EisenbergR."/>
  <result pre="T.AtanasiuD.LouH.EisenbergR. J.CohenG. H. (2013). Displacement of the C terminus of" exact="herpes" post="simplex virus gD is sufficient to expose the fusion-activating"/>
  <result pre="A. (1998). CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by" exact="primary" post="human immunodeficiency virus type 1 isolates.J. Virol.723475â€&quot;3478.9525686 GompelsU.MinsonA. (1986)."/>
  <result pre="CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human" exact="immunodeficiency" post="virus type 1 isolates.J. Virol.723475â€&quot;3478.9525686 GompelsU.MinsonA. (1986). The properties"/>
  <result pre="protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus" exact="type 1" post="isolates.J. Virol.723475â€&quot;3478.9525686 GompelsU.MinsonA. (1986). The properties and sequence of"/>
  <result pre="GompelsU.MinsonA. (1986). The properties and sequence of glycoprotein H of" exact="herpes" post="simplex virus type 1.Virology153230â€&quot;247. 10.1016/0042-6822(86)90026-73016991 HaaseA. T. (2005). Perils"/>
  <result pre="R.PrinciottoA.et al. (2009). Soluble CD4 and CD4-mimetic compounds inhibit HIV-1" exact="infection" post="by induction of a short-lived activated state.PLoS Pathog.5:e100036010.1371/journal.ppat.1000360 HalsteadS."/>
  <result pre="and clinical update.Expert Opin. Investig. Drugs27951â€&quot;962. 10.1080/13543784.2018.1548609 HarrisonS. C. (2008)." exact="Viral" post="membrane fusion.Nat. Struct. Mol. Biol.15690â€&quot;698. 10.1038/nsmb.145618596815 HarrisonS. C. (2015)."/>
  <result pre="Viral membrane fusion.Nat. Struct. Mol. Biol.15690â€&quot;698. 10.1038/nsmb.145618596815 HarrisonS. C. (2015)." exact="Viral" post="membrane fusion.Virology47498â€&quot;507. 10.1016/j.virol.2015.03.043 HeldweinE. E.LouH.BenderF. C.CohenG. H.EisenbergR. J.HarrisonS. C."/>
  <result pre="H.EisenbergR. J.HarrisonS. C. (2006). Crystal structure of glycoprotein B from" exact="herpes" post="simplex virus 1.Science313217â€&quot;220. 10.1126/science.112654816840698 HolthausenD. J.LeeS. H.KumarV. T.BouvierN. M.KrammerF.EllebedyA."/>
  <result pre="Res.137225â€&quot;234. 10.1016/j.virusres.2008.07.02218723056 HungJ. J.HsiehM. T.YoungM. J.KaoC. L.KingC. C.ChangW. (2004). An" exact="external" post="loop region of domain III of dengue virus type"/>
  <result pre="An external loop region of domain III of dengue virus" exact="type 2" post="envelope protein is involved in serotype-specific binding to mosquito"/>
  <result pre="M.IsraelR. J.LowyI.OstrowN. A.VassilatosL. S.BarishM.et al. (2004). Treatment of advanced human" exact="immunodeficiency" post="virus type 1 disease with the viral entry inhibitor"/>
  <result pre="A.VassilatosL. S.BarishM.et al. (2004). Treatment of advanced human immunodeficiency virus" exact="type 1" post="disease with the viral entry inhibitor PRO 542.Antimicrob. Agents"/>
  <result pre="al. (2004). Treatment of advanced human immunodeficiency virus type 1" exact="disease" post="with the viral entry inhibitor PRO 542.Antimicrob. Agents Chemother.48423â€&quot;429."/>
  <result pre="of advanced human immunodeficiency virus type 1 disease with the" exact="viral" post="entry inhibitor PRO 542.Antimicrob. Agents Chemother.48423â€&quot;429. 10.1128/aac.48.2.423-429.200414742190 JacobsonJ. M.LowyI.FletcherC."/>
  <result pre="(2000). Single-dose safety, pharmacology, and antiviral activity of the human" exact="immunodeficiency" post="virus (HIV) type 1 entry inhibitor PRO 542 in"/>
  <result pre="pharmacology, and antiviral activity of the human immunodeficiency virus (HIV)" exact="type 1" post="entry inhibitor PRO 542 in HIV-infected adults.J. Infect. Dis.182326â€&quot;329."/>
  <result pre="inhibition by a peptide.Nature365:11310.1038/365113a0 JiangS.LinK.StrickN.NeurathA. R. (1993b). Inhibition of HIV-1" exact="infection" post="by a fusion domain binding peptide from the HIV-1"/>
  <result pre="pharmacokinetics of recombinant soluble CD4 (rCD4) in subjects with the" exact="acquired immunodeficiency syndrome" post="(AIDS) and AIDS-related complex. A phase 1 study.Ann. Intern."/>
  <result pre="of recombinant soluble CD4 (rCD4) in subjects with the acquired" exact="immunodeficiency" post="syndrome (AIDS) and AIDS-related complex. A phase 1 study.Ann."/>
  <result pre="recombinant soluble CD4 (rCD4) in subjects with the acquired immunodeficiency" exact="syndrome" post="(AIDS) and AIDS-related complex. A phase 1 study.Ann. Intern."/>
  <result pre="(rCD4) in subjects with the acquired immunodeficiency syndrome (AIDS) and" exact="AIDS-related complex." post="A phase 1 study.Ann. Intern. Med.112254â€&quot;261. 10.7326/0003-4819-112-4-2297204 KimberlinD. W.WhitleyR."/>
  <result pre="J.TrottierB.et al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant" exact="HIV infection" post="in North and South America.N. Engl. J. Med.3482175â€&quot;2185. 10.1056/NEJMoa03502612637625"/>
  <result pre="al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV" exact="infection" post="in North and South America.N. Engl. J. Med.3482175â€&quot;2185. 10.1056/NEJMoa03502612637625"/>
  <result pre="Med.3482175â€&quot;2185. 10.1056/NEJMoa03502612637625 LeeC. C.LinL. L.ChanW. E.KoT. P.LaiJ. S.WangA. H. (2013)." exact="Structural" post="basis for the antibody neutralization of herpes simplex virus.Acta"/>
  <result pre="S.WangA. H. (2013). Structural basis for the antibody neutralization of" exact="herpes" post="simplex virus.Acta Crystallogr. D Biol. Crystallogr.69(Pt 10)1935â€&quot;1945. 10.1107/S090744491301677624100313 LiH.GuanY.SzczepanskaA.Moreno-VargasA."/>
  <result pre="recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion" exact="intermediate" post="induced by CD4 D1D2 domains.Retrovirology9:10410.1186/1742-4690-9-104 LuL.YuF.CaiL.DebnathA. K.JiangS. (2016). Development"/>
  <result pre="Genes35175â€&quot;186. 10.1007/s11262-007-0103-217508277 MelikyanG. B. (2008). Common principles and intermediates of" exact="viral" post="protein-mediated fusion: the HIV-1 paradigm.Retrovirology5:11110.1186/1742-4690-5-111 ModisY.OgataS.ClementsD.HarrisonS. C. (2003). A"/>
  <result pre="and autoimmunity.Expert Rev. Vaccines15607â€&quot;617. 10.1586/14760584.2016.112309826588466 MubarakA.AlturaikiW.HemidaM. G. (2019). Middle east" exact="respiratory" post="syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development.J."/>
  <result pre="autoimmunity.Expert Rev. Vaccines15607â€&quot;617. 10.1586/14760584.2016.112309826588466 MubarakA.AlturaikiW.HemidaM. G. (2019). Middle east respiratory" exact="syndrome" post="coronavirus (MERS-CoV): infection, immunological response, and vaccine development.J. Immunol."/>
  <result pre="NgK. E. (2019). Xofluza (Baloxavir Marboxil) for the treatment of" exact="acute" post="uncomplicated influenza.P T449â€&quot;11.30675086 NicolaA. V. (2016). Herpesvirus entry into"/>
  <result pre="endosomal low pH.Traffic17965â€&quot;975. 10.1111/tra.1240827126894 NicolaA. V.StrausS. E. (2004). Cellular and" exact="viral" post="requirements for rapid endocytic entry of herpes simplex virus.J."/>
  <result pre="(2004). Cellular and viral requirements for rapid endocytic entry of" exact="herpes" post="simplex virus.J. Virol.787508â€&quot;7517. 10.1128/JVI.78.14.7508-7517.200415220424 OrloffS. L.KennedyM. S.BelperronA. A.MaddonP. J.McDougalJ."/>
  <result pre="(1993). Two mechanisms of soluble CD4 (sCD4)-mediated inhibition of human" exact="immunodeficiency" post="virus type 1 (HIV-1) infectivity and their relation to"/>
  <result pre="mechanisms of soluble CD4 (sCD4)-mediated inhibition of human immunodeficiency virus" exact="type 1" post="(HIV-1) infectivity and their relation to primary HIV-1 isolates"/>
  <result pre="immunodeficiency virus type 1 (HIV-1) infectivity and their relation to" exact="primary" post="HIV-1 isolates with reduced sensitivity to sCD4.J. Virol.671461â€&quot;1471.8437224 PaleseP.ShawM."/>
  <result pre="(2009). Combinations of the first and next generations of human" exact="immunodeficiency" post="virus (HIV) fusion inhibitors exhibit a highly potent synergistic"/>
  <result pre="highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV" exact="type 1" post="strains.J. Virol.837862â€&quot;7872. 10.1128/JVI.00168-0919493996 PanyaA.BangphoomiK.ChoowongkomonK.YenchitsomanusP. T. (2014). Peptide inhibitors against"/>
  <result pre="10.1042/BCJ2017066229343613 ParajuliB.AcharyaK.YuR.NgoB.RashadA. A.AbramsC. F.et al. (2016). Lytic inactivation of human" exact="immunodeficiency" post="virus by dual engagement of gp120 and gp41 domains"/>
  <result pre="PerezE. E.RileyJ. L.CarrollR. G.von LaerD.JuneC. H. (2005). Suppression of HIV-1" exact="infection" post="in primary CD4 T cells transduced with a self-inactivating"/>
  <result pre="L.CarrollR. G.von LaerD.JuneC. H. (2005). Suppression of HIV-1 infection in" exact="primary" post="CD4 T cells transduced with a self-inactivating lentiviral vector"/>
  <result pre="Dis.10.1093/infdis/jiaa061[Epub ahead of print]. SatohT.AriiJ.SuenagaT.WangJ.KogureA.UehoriJ.et al. (2008). PILRalpha is a" exact="herpes" post="simplex virus-1 entry coreceptor that associates with glycoprotein B.Cell132935â€&quot;944."/>
  <result pre="al. (1990). Recombinant soluble CD4 therapy in patients with the" exact="acquired immunodeficiency syndrome" post="(AIDS) and AIDS-related complex. A phase I-II escalating dosage"/>
  <result pre="(1990). Recombinant soluble CD4 therapy in patients with the acquired" exact="immunodeficiency" post="syndrome (AIDS) and AIDS-related complex. A phase I-II escalating"/>
  <result pre="Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency" exact="syndrome" post="(AIDS) and AIDS-related complex. A phase I-II escalating dosage"/>
  <result pre="therapy in patients with the acquired immunodeficiency syndrome (AIDS) and" exact="AIDS-related complex." post="A phase I-II escalating dosage trial.Ann. Intern. Med.112247â€&quot;253. 10.7326/0003-4819-112-4-2472297203"/>
  <result pre="for therapeutic applications: a review.Molecules1712276â€&quot;12286. 10.3390/molecules17101227623079498 SharmaD.BalamuraliM. M.ChakrabortyK.KumaranS.JeganathanS.RashidU.et al. (2005)." exact="Protein" post="minimization of the gp120 binding region of human CD4.Biochemistry4416192â€&quot;16202."/>
  <result pre="Natl. Acad. Sci. U.S.A.107866â€&quot;871. 10.1073/pnas.091335110720080767 SuiJ.HwangW. C.PerezS.WeiG.AirdD.ChenL. M.et al. (2009)." exact="Structural" post="and functional bases for broad-spectrum neutralization of avian and"/>
  <result pre="Biol.16265â€&quot;273. 10.1038/nsmb.156619234466 SullivanN.SunY.BinleyJ.LeeJ.BarbasC. F.IIIParrenP. W.et al. (1998). Determinants of human" exact="immunodeficiency" post="virus type 1 envelope glycoprotein activation by soluble CD4"/>
  <result pre="SullivanN.SunY.BinleyJ.LeeJ.BarbasC. F.IIIParrenP. W.et al. (1998). Determinants of human immunodeficiency virus" exact="type 1" post="envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.J."/>
  <result pre="Biol.79072â€&quot;82. 10.1007/978-1-4614-7651-1_423884586 TakashitaE.KawakamiC.OgawaR.MoritaH.FujisakiS.ShirakuraM.et al. (2019). Influenza A(H3N2) virus exhibiting reduced" exact="susceptibility to" post="baloxavir due to a polymerase acidic subunit I38T substitution"/>
  <result pre="prior baloxavir treatment, Japan, January 2019.Euro Surveill.24:190017010.2807/1560-7917.ES.2019.24.12.1900170 TianY. S.ZhouY.TakagiT.KameokaM.KawashitaN. (2018)." exact="Dengue" post="virus and its inhibitors: a brief review.Chem. Pharm. Bull.66191â€&quot;206."/>
  <result pre="Pharm. Bull.66191â€&quot;206. 10.1248/cpb.c17-0079429491253 TrauneckerA.LukeW.KarjalainenK. (1988). Soluble CD4 molecules neutralize human" exact="immunodeficiency" post="virus type 1.Nature33184â€&quot;86. 10.1038/331084a02829024 TrkolaA.PomalesA. B.YuanH.KorberB.MaddonP. J.AllawayG. P.et al."/>
  <result pre="10.1038/331084a02829024 TrkolaA.PomalesA. B.YuanH.KorberB.MaddonP. J.AllawayG. P.et al. (1995). Cross-clade neutralization of" exact="primary" post="isolates of human immunodeficiency virus type 1 by human"/>
  <result pre="P.et al. (1995). Cross-clade neutralization of primary isolates of human" exact="immunodeficiency" post="virus type 1 by human monoclonal antibodies and tetrameric"/>
  <result pre="(1995). Cross-clade neutralization of primary isolates of human immunodeficiency virus" exact="type 1" post="by human monoclonal antibodies and tetrameric CD4-IgG.J. Virol.696609â€&quot;6617.7474069 VigantF.SantosN."/>
  <result pre="and tetrameric CD4-IgG.J. Virol.696609â€&quot;6617.7474069 VigantF.SantosN. C.LeeB. (2015). Broad-spectrum antivirals against" exact="viral" post="fusion.Nat. Rev. Microbiol.13426â€&quot;437. 10.1038/nrmicro347526075364 VitaC.DrakopoulouE.VizzavonaJ.RochetteS.MartinL.MenezA.et al. (1999). Rational engineering"/>
  <result pre="Natl. Acad. Sci. U.S.A.9613091â€&quot;13096. 10.1073/pnas.96.23.1309110557278 WangX.ZouP.WuF.LuL.JiangS. (2017). Development of small-molecule" exact="viral" post="inhibitors targeting various stages of the life cycle of"/>
  <result pre="(1994). Peptides corresponding to a predictive alpha-helical domain of human" exact="immunodeficiency" post="virus type 1 gp41 are potent inhibitors of virus"/>
  <result pre="corresponding to a predictive alpha-helical domain of human immunodeficiency virus" exact="type 1" post="gp41 are potent inhibitors of virus infection.Proc. Natl. Acad."/>
  <result pre="M.WenZ.ChengY.HuangW. K.QianX.et al. (2016). Identification of small-molecule inhibitors of Zika" exact="virus infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="K.QianX.et al. (2016). Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
  <result pre="targeting the hemagglutinin.Viruses5352â€&quot;373. 10.3390/v501035223340380 YuY.DengY. Q.ZouP.WangQ.DaiY.YuF.et al. (2017). A peptide-based" exact="viral" post="inactivator inhibits Zika virus infection in pregnant mice and"/>
  <result pre="YuY.DengY. Q.ZouP.WangQ.DaiY.YuF.et al. (2017). A peptide-based viral inactivator inhibits Zika" exact="virus infection" post="in pregnant mice and fetuses.Nat. Commun.8:1567210.1038/ncomms15672 ZamanR.IslamR. A.IbnatN.OthmanI.ZainiA.LeeC. Y.et"/>
  <result pre="Q.ZouP.WangQ.DaiY.YuF.et al. (2017). A peptide-based viral inactivator inhibits Zika virus" exact="infection" post="in pregnant mice and fetuses.Nat. Commun.8:1567210.1038/ncomms15672 ZamanR.IslamR. A.IbnatN.OthmanI.ZainiA.LeeC. Y.et"/>
  <result pre="al. (2016). Two distinct trimeric conformations of natively membrane-anchored full-length" exact="herpes" post="simplex virus 1 glycoprotein B.Proc. Natl. Acad. Sci. U.S.A.1134176â€&quot;4181."/>
 </snippets>
</snippetsTree>
